Recently, the CXCR2 receptor for the granulocyte- and platelet-derived ligand CXCL5/7 was shown to be important for recruitment of neutrophils to early metastatic niches [92], and CXCR2 inhibitors reduce the recruitment of granulocytes in primary tumor sites as well [103, 104]. The gene discussed is CXCR2; the disease is neoplasm.